Certainty index
Moderate certainty — page 3
The true effect is likely to be close to the estimate, but there is a possibility that it is substantially different. Further research is likely to have an important impact on confidence in the estimate.
Graded outcomes
114 documents · page 3 of 3
Table 1. Outcomes and syntheses graded at moderate certainty, on this page.
| Document | Type | Effect or conclusion as recorded |
|---|---|---|
| SS-31 (elamipretide) in primary mitochondrial myopathy and bioenergetic disorders: effect on the anchor… | Synthesis | Moderate certainty evidence from 2 contributing trials bears on the effect of SS-31 (elamipretide) on the anchor outcome for primary mitochondrial myopathy and bioenergetic disorders. The estimate… |
| Tesamorelin in hiv-associated lipodystrophy and excess visceral adiposity: effect on the anchor outcome | Synthesis | Moderate certainty evidence from 2 contributing trials bears on the effect of Tesamorelin on the anchor outcome for hiv-associated lipodystrophy and excess visceral adiposity. The estimate the… |
| Tirzepatide in atherosclerotic cardiovascular disease and cardiovascular risk reduction: effect on the anchor… | Synthesis | Moderate certainty evidence from 2 contributing trials bears on the effect of Tirzepatide on the anchor outcome for atherosclerotic cardiovascular disease and cardiovascular risk reduction. The… |
| Retatrutide in obesity and overweight in adults: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 5 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| CagriSema (cagrilintide with semaglutide) in obesity and overweight in adults: tolerability and… | Synthesis | Moderate certainty evidence from 4 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Orforglipron in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 4 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Survodutide in obesity and overweight in adults: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 4 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Thymosin alpha-1 in immune modulation and adjunctive immunotherapy: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 4 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Mazdutide in obesity and overweight in adults: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 3 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Mazdutide in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 3 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Orforglipron in obesity and overweight in adults: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 3 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Teduglutide in inflammatory bowel disease and mucosal barrier disorders: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 3 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| CagriSema (cagrilintide with semaglutide) in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Gonadorelin in growth hormone deficiency and growth-hormone secretagogue pharmacology: tolerability and… | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Kisspeptin-10 in growth hormone deficiency and growth-hormone secretagogue pharmacology: tolerability and… | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Larazotide acetate in inflammatory bowel disease and mucosal barrier disorders: tolerability and… | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Liraglutide in adjunctive therapy in type 1 diabetes: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Semaglutide, oral in atherosclerotic cardiovascular disease and cardiovascular risk reduction: tolerability… | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| PT-141 (bremelanotide) in hypoactive sexual desire and erectile dysfunction: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Retatrutide in type 2 diabetes mellitus: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Semaglutide in heart failure with preserved ejection fraction and obesity: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| SS-31 (elamipretide) in primary mitochondrial myopathy and bioenergetic disorders: tolerability and… | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Tesamorelin in hiv-associated lipodystrophy and excess visceral adiposity: tolerability and discontinuation | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Tirzepatide in atherosclerotic cardiovascular disease and cardiovascular risk reduction: tolerability and… | Synthesis | Moderate certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
| Retatrutide in obesity and overweight in adults: durability of effect | Synthesis | Moderate certainty evidence bears on whether the effect of Retatrutide in obesity and overweight in adults is maintained across the randomised period. The contributing trials range in duration and… |
| CagriSema (cagrilintide with semaglutide) in obesity and overweight in adults: durability of effect | Synthesis | Moderate certainty evidence bears on whether the effect of CagriSema (cagrilintide with semaglutide) in obesity and overweight in adults is maintained across the randomised period. The contributing… |
| Orforglipron in type 2 diabetes mellitus: durability of effect | Synthesis | Moderate certainty evidence bears on whether the effect of Orforglipron in type 2 diabetes mellitus is maintained across the randomised period. The contributing trials range in duration and the… |
| Survodutide in obesity and overweight in adults: durability of effect | Synthesis | Moderate certainty evidence bears on whether the effect of Survodutide in obesity and overweight in adults is maintained across the randomised period. The contributing trials range in duration and… |
| Thymosin alpha-1 in immune modulation and adjunctive immunotherapy: durability of effect | Synthesis | Moderate certainty evidence bears on whether the effect of Thymosin alpha-1 in immune modulation and adjunctive immunotherapy is maintained across the randomised period. The contributing trials range… |
| Mazdutide in obesity and overweight in adults: durability of effect | Synthesis | Moderate certainty evidence bears on whether the effect of Mazdutide in obesity and overweight in adults is maintained across the randomised period. The contributing trials range in duration and the… |
| Mazdutide in type 2 diabetes mellitus: durability of effect | Synthesis | Moderate certainty evidence bears on whether the effect of Mazdutide in type 2 diabetes mellitus is maintained across the randomised period. The contributing trials range in duration and the… |
| Orforglipron in obesity and overweight in adults: durability of effect | Synthesis | Moderate certainty evidence bears on whether the effect of Orforglipron in obesity and overweight in adults is maintained across the randomised period. The contributing trials range in duration and… |
| Teduglutide in inflammatory bowel disease and mucosal barrier disorders: durability of effect | Synthesis | Moderate certainty evidence bears on whether the effect of Teduglutide in inflammatory bowel disease and mucosal barrier disorders is maintained across the randomised period. The contributing trials… |
| CagriSema (cagrilintide with semaglutide) in type 2 diabetes mellitus: durability of effect | Synthesis | Moderate certainty evidence bears on whether the effect of CagriSema (cagrilintide with semaglutide) in type 2 diabetes mellitus is maintained across the randomised period. The contributing trials… |
page 3 of 3